



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/871,353	05/30/2001	Franco Cipriani	13706	9560

23676 7590 01/29/2003

SHELDON & MAK, INC  
225 SOUTH LAKE AVENUE  
9TH FLOOR  
PASADENA, CA 91101

EXAMINER

TRAN, MY CHAU T

ART UNIT PAPER NUMBER

1639

DATE MAILED: 01/29/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/871,353

Applicant(s)

CIPRIANI ET AL.

Examiner

My-Chau T. Tran

Art Unit

1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 04 November 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) 8-13 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4 is/are rejected.
- 7) ☒ Claim(s) 5-7 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 7.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

## DETAILED ACTION

### *Election/Restrictions*

1. Applicant's election of Group I (Claims 1-7) in Paper No. 10 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Applicant has indicated that should patentable patent matter be found in the elected claims (Claims 1-7) applicant reserves the right to rejoin one or more of the non-elected claims (Claims 8-13). Applicants are advised that in accordance with the court decisions in *In re Ochiai*, {71 F.3d 1565, 37 USPQ2d 1127 (Fed. Cir. 1995)} and *In re Brouwer* {77 F.3d 422, 37 USPQ2d 1663 (Fed. Cir. 1996)}, in the event that a product claim (Claims 1-7) is found to be allowable, a method of use claim, *which is of the same scope as the allowed product claim*, may be rejoined with the allowed product claim.

2. Claims 8-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 10.

### *Priority*

3. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Art Unit: 1639

4. Claims 1-7 are treated on the merit in this Office Action.

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Berlin et al. (*J. Am. Chem. Soc.*, **1998**, 120(51):13453-13460).

Berlin et al. disclosed a bithiophene and terthiophene molecules (thiophene oligomers) that is terminated with the carboxylic moiety (functional group) (ref. #4, and 5 of Chart 1, pg. 13454; pg. 13454, left col., lines 1-6) (refer to claims 1-4). Both thiophene oligomers are excitable in the UV-visible region (pg. 13457, left col., lines 52-60). The linear bithiophene can be coupled to polythiophene (organic molecules). Therefore, the bithiophene and terthiophene molecules of Berlin et al. anticipate the presently claimed thiophene oligomers.

***Claim Rejections - 35 USC § 103***

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1639

8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 1-<sup>4</sup>~~3~~ are rejected under 35 U.S.C. 103(a) as being unpatentable over Berlin et al. (*J. Am. Chem. Soc.*, **1998**, 120(51):13453-13460) in view of Roncucci et al. (US Patent 5,869,051).

Berlin et al. disclosed a bithiophene and terthiophene molecules (thiophene oligomers) that is terminated with the carboxylic moiety (functional group) (ref. #4, and 5 of Chart 1, pg. 13454; pg. 13454, left col., lines 1-6) (refer to claims 1-4). Both thiophene oligomers are excitable in the UV-visible region (pg. 13457, left col., lines 52-60). The linear bithiophene can be coupled to polythiophene (organic molecules).

The thiophene oligomers of Berlin et al. do not expressly disclose that the thiophene oligomers can form covalent bond with biological molecules.

Roncucci et al. discloses a terthiophene (col. 1, lines 60-64) that is derivatized with functional group that is able to react with amino group of peptides or proteins (biological molecules) (col. 2, lines 13). The functional group includes CHO and COOH (col. 3, Example 1;

Art Unit: 1639

col. 4, Example 3). These conjugates would be able to work out a biocidal action on various kinds of cells once activated with radiation in near UV (col. 1, lines 12-15).

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to include forming a covalent bond between the thiophene oligomer and biological molecule as taught by Roncucci et al. in the thiophene oligomers of Berlin et al.. One of ordinary skill in the art would have been motivated to include a covalent bond between the thiophene oligomer and biological molecule in the thiophene oligomers of Berlin et al. for the advantage of providing a conjugate that would be able to work out a biocidal action on various kinds of cells once activated with radiation in near UV (Roncucci: col. 1, lines 12-15). Since both Berlin et al. and Roncucci et al. disclose the same type of thiophene oligomer, which is terthiophene (Berlin: pg. 13454, ref. #4, and 5 of Chart 1; Roncucci: col. 1, lines 60-64).

#### ***Allowable Subject Matter***

10. Claims 5-7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to My-Chau T. Tran whose telephone number is 703-305-6999. The examiner is on ***Increased Flex Schedule*** and can normally be reached on Monday: 8:00-2:30; Tuesday-Thursday: 7:30-5:00; Friday: 8:00-3:30.

Application/Control Number: 09/871,353  
Art Unit: 1639

Page 6

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew J. Wang can be reached on 703-306-3217. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1123.

mct  
January 24, 2003

  
**PADMASHRI PONNALURI**  
**PRIMARY EXAMINER**